Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Recruiting · Phase 1 · NCT04777994
Conditions: Advanced Solid Tumor Cancer
At a glance
- Research payments reported, 2025
- $964,459
- U.S. investigators named
- 17
- Sites paid
- 23
- Planned or actual enrollment
- 248
About the trial
- Sponsor
- Calico Life Sciences LLC
- Tested
- ABBV-CLS-484 (drug), Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) (drug), Programmed Cell Death-1 (PD-1) Inhibitor (drug)
- Dates
- Started 2021-03-09; completion 2026-10
- Results posted
- Not yet
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation and Part 3 Dose Expansion (Monotherapy and Combination therapy). Part 1, ABBV-CLS-484 will be administered alone in escalating dose levels to eligible subjects who have advanced solid tumors. Part 2, ABBV-CLS-484 will …
From ClinicalTrials.gov, last updated 2026-06-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $964,459 in research payments for this study in 2025 (117 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alejandro Recio Boiles, M.D. State or Local Public Health Clinic/Center · Tucson, AZ
- Yana G. Najjar, M.D. Student in an Organized Health Care Education/Training Program · Washington, DC
- David F. Mcdermott, MD Hematology & Oncology · Boston, MA
- Kartik Sehgal, MD Hematology & Oncology · Boston, MA
- Carole Fakhry, MD ENT (Otolaryngology) · Baltimore, MD
- Tanguy Y. Seiwert, M.D. Medical Oncology · Baltimore, MD
- Patricia M. Lorusso, DO Medical Oncology · Detroit, MI
- Ulka N. Vaishampayan, MD Internal Medicine · Ann Arbor, MI
- Michael R. Harrison, M.D. Medical Oncology · Durham, NC
- John D. Powderly II, M.D. Hematology & Oncology · Huntersville, NC
- Janice M. Mehnert Medical Oncology · New York, NY
- Jason Luke, M.D. Hematology & Oncology · Pittsburgh, PA
- Lova L. Sun, MD Medical Oncology · Philadelphia, PA
- Benedito A. Carneiro, MD Medical Oncology · Providence, RI
- Hans J. Hammers, M.D., PH.D. Medical Oncology · Dallas, TX
- Eric Jonasch, M.D. Medical Oncology · Houston, TX
- David Sommerhalder Hematology & Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Pittsburgh Cancer $297,414
- University of Michigan Health System, MI $169,590
- Hospital of Univ of Pennsylvania, PA $55,957
- Beth Israel Deaconess Medical Center $52,584
- Yale University $51,075
- Ut MD Anderson Cancer Center $44,073
- Danafarbermass General Brigham Cancer Care Inc $37,380
- Duke University $35,721
- Rhode Island Hospital, RI $35,497
- Dana Farber Cancer Institute $32,635
- The University of Arizona $25,653
- University of Texas Southwestern Medical Center $17,640
- NYU Langone Health $17,640
- Campus Health Services $17,640
- Johns Hopkins University School of Medicine $17,640
- $17,297
- The Johns Hopkins University $12,916
- The University of Texas $12,562
- New Experimental Therapeutics of San Antonio LLC $6,537
- UPMC Hillman Cancer Center $2,100
- Yale School of Medicine $2,100
- Carolina Biooncology Insitute PLLC $1,060
- Next Oncology $875
- Carolina Biooncology Institute $875
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.